î
îž
î
Baxter International Inc
BAX23.810USD
-0.180-0.75%
āļāļīāļÂ 09/15, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
12.23BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Baxter International Inc āļāļĢāļīāļĐāļąāļ
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
āļāđāļāļĄāļđāļĨāļāļĢāļīāļĐāļąāļî
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBAX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļBaxter International Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 15, 1961
āļāļĩāļāļĩāđāļMr. Andrew P. Hider
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ38000
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 15
āļāļĩāđāļāļĒāļđāđOne Baxter Parkway
āđāļĄāļ·āļāļDEERFIELD
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNYSE Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ60015
āđāļāļĢāļĻāļąāļāļāđ12249482000
āđāļ§āđāļāđāļāļāđhttps://www.baxter.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļBAX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 15, 1961
āļāļĩāļāļĩāđāļMr. Andrew P. Hider
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļî
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Ms. Heather Knight
Ms. Heather Knight
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
177.32K
+11.79%
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. Alok Sonig
Mr. Alok Sonig
Executive Vice President, Group President - Pharmaceuticals
Executive Vice President, Group President - Pharmaceuticals
127.11K
-2.45%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
Ms. Catherine R. (Cathy) Smith
Ms. Catherine R. (Cathy) Smith
Independent Director
Independent Director
30.23K
+31.17%
Ms. Patricia B. (Patty) Morrison
Ms. Patricia B. (Patty) Morrison
Independent Director
Independent Director
22.94K
+45.58%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Director
Independent Director
16.45K
+77.49%
Mr. Jeffrey A. (Jay) Craig
Mr. Jeffrey A. (Jay) Craig
Independent Director
Independent Director
10.65K
+206.88%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Andrew P. Hider
Mr. Andrew P. Hider
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.05K
--
Ms. Heather Knight
Ms. Heather Knight
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies
177.32K
+11.79%
Dr. Jeanne K. Mason, Ph.D.
Dr. Jeanne K. Mason, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
141.67K
+7.47%
Mr. Alok Sonig
Mr. Alok Sonig
Executive Vice President, Group President - Pharmaceuticals
Executive Vice President, Group President - Pharmaceuticals
127.11K
-2.45%
Mr. David S. Rosenbloom
Mr. David S. Rosenbloom
Executive Vice President, General Counsel
Executive Vice President, General Counsel
101.60K
-14.01%
Dr. Stephen N. (Steve) Oesterle, M.D.
Dr. Stephen N. (Steve) Oesterle, M.D.
Independent Director
Independent Director
35.70K
+25.18%
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Infusion Therapies and Technologies
994.00M
37.87%
Care and Connectivity Solutions
427.00M
16.27%
Injectables and Anesthesia
335.00M
12.76%
Front Line Care
277.00M
10.55%
Advanced Surgery
268.00M
10.21%
āļāļ·āđāļ āđ
324.00M
12.34%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
United States
1.49B
56.76%
International
1.14B
43.24%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Infusion Therapies and Technologies
994.00M
37.87%
Care and Connectivity Solutions
427.00M
16.27%
Injectables and Anesthesia
335.00M
12.76%
Front Line Care
277.00M
10.55%
Advanced Surgery
268.00M
10.21%
āļāļ·āđāļ āđ
324.00M
12.34%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 19 āļŠ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 19 āļŠ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
12.06%
Pzena Investment Management, LLC
10.80%
Dodge & Cox
10.15%
BlackRock Institutional Trust Company, N.A.
5.81%
State Street Global Advisors (US)
4.27%
āļāļ·āđāļ āđ
56.91%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
12.06%
Pzena Investment Management, LLC
10.80%
Dodge & Cox
10.15%
BlackRock Institutional Trust Company, N.A.
5.81%
State Street Global Advisors (US)
4.27%
āļāļ·āđāļ āđ
56.91%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor/Hedge Fund
46.91%
Investment Advisor
44.39%
Hedge Fund
3.20%
Research Firm
2.06%
Pension Fund
1.76%
Insurance Company
1.45%
Bank and Trust
1.29%
Sovereign Wealth Fund
1.14%
Individual Investor
0.46%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q2
1877
507.74M
98.85%
-23.16M
2025Q1
1934
508.09M
99.01%
-37.41M
2024Q4
1984
501.11M
97.98%
-41.68M
2024Q3
2005
485.40M
95.14%
-42.32M
2024Q2
2042
472.72M
92.77%
-47.98M
2024Q1
2091
469.13M
92.11%
-57.76M
2023Q4
2137
471.69M
92.98%
-44.04M
2023Q3
2123
465.39M
91.91%
-35.52M
2023Q2
2140
458.55M
90.66%
-30.65M
2023Q1
2123
459.27M
90.86%
-22.24M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļî
āļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
The Vanguard Group, Inc.
60.82M
11.85%
+290.58K
+0.48%
Mar 31, 2025
Pzena Investment Management, LLC
36.77M
7.17%
+3.13M
+9.32%
Mar 31, 2025
Dodge & Cox
51.46M
10.03%
-122.48K
-0.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
30.27M
5.9%
+743.24K
+2.52%
Mar 31, 2025
State Street Global Advisors (US)
21.77M
4.24%
-21.20K
-0.10%
Mar 31, 2025
T. Rowe Price Associates, Inc.
19.57M
3.81%
+4.32M
+28.32%
Mar 31, 2025
BlackRock Financial Management, Inc.
17.99M
3.51%
+419.98K
+2.39%
Mar 31, 2025
Geode Capital Management, L.L.C.
12.56M
2.45%
+109.37K
+0.88%
Mar 31, 2025
Harris Associates L.P.
9.00M
1.75%
+540.70K
+6.39%
Mar 31, 2025
BlackRock Investment Management, LLC
6.99M
1.36%
+2.18M
+45.23%
Mar 31, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 2 āļŠ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 2 āļŠ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
Cullen Enhanced Equity Income ETF
2.77%
iShares Large Cap Value Active ETF
2.32%
First Trust Indxx Medical Devices ETF
1.96%
iShares U.S. Medical Devices ETF
1.77%
SPDR S&P Health Care Equipment ETF
1.76%
North Shore Equity Rotation ETF
1.68%
Invesco S&P 500 Equal Weight Health Care ETF
1.6%
VanEck Morningstar SMID Moat ETF
1.2%
Humankind US Stock ETF
0.96%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
0.81%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Cullen Enhanced Equity Income ETF
āļŠāļąāļāļŠāđāļ§āļ2.77%
iShares Large Cap Value Active ETF
āļŠāļąāļāļŠāđāļ§āļ2.32%
First Trust Indxx Medical Devices ETF
āļŠāļąāļāļŠāđāļ§āļ1.96%
iShares U.S. Medical Devices ETF
āļŠāļąāļāļŠāđāļ§āļ1.77%
SPDR S&P Health Care Equipment ETF
āļŠāļąāļāļŠāđāļ§āļ1.76%
North Shore Equity Rotation ETF
āļŠāļąāļāļŠāđāļ§āļ1.68%
Invesco S&P 500 Equal Weight Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.6%
VanEck Morningstar SMID Moat ETF
āļŠāļąāļāļŠāđāļ§āļ1.2%
Humankind US Stock ETF
āļŠāļąāļāļŠāđāļ§āļ0.96%
Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx
āļŠāļąāļāļŠāđāļ§āļ0.81%
āđāļāļīāļāļāļąāļāļāļĨî
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
2.75B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
Feb 11, 2025
BAX.NB Interim Cash Dividend of gross USD 0.17 paid on Apr 01, 2025 going ex on Feb 28, 2025 with reinvestment option
Feb 28, 2025
Apr 01, 2025
Feb 28, 2025
Nov 11, 2024
BAX.NB Final Cash Dividend of gross USD 0.17 paid on Jan 02, 2025 going ex on Nov 29, 2024 with reinvestment option
Nov 29, 2024
Jan 02, 2025
Nov 29, 2024
Jul 16, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 01, 2024 going ex on Aug 30, 2024 with reinvestment option
Aug 30, 2024
Oct 01, 2024
Aug 30, 2024
May 07, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 01, 2024 going ex on May 31, 2024 with reinvestment option
May 31, 2024
Jul 01, 2024
May 31, 2024
Feb 12, 2024
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 01, 2024 going ex on Feb 29, 2024 with reinvestment option
Mar 01, 2024
Apr 01, 2024
Feb 29, 2024
Nov 14, 2023
BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 02, 2024 going ex on Nov 30, 2023 with reinvestment option
Dec 01, 2023
Jan 02, 2024
Nov 30, 2023
Jul 18, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Oct 02, 2023 going ex on Aug 31, 2023 with reinvestment option
Sep 01, 2023
Oct 02, 2023
Aug 31, 2023
May 01, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Jul 03, 2023 going ex on Jun 01, 2023
Jun 02, 2023
Jul 03, 2023
Jun 01, 2023
Feb 14, 2023
BAX.NB Interim Cash Dividend of gross USD 0.29 paid on Apr 03, 2023 going ex on Feb 23, 2023 with reinvestment option
Feb 24, 2023
Apr 03, 2023
Feb 23, 2023
Nov 15, 2022
BAX.NB Final Cash Dividend of gross USD 0.29 paid on Jan 03, 2023 going ex on Dec 01, 2022
Dec 02, 2022
Jan 03, 2023
Dec 01, 2022
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļî
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
